Citation Impact
Citing Papers
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
2018 StandoutNobel
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
2014 Standout
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
2016
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
2013
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
2016
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
2015
Breast cancer statistics, 2019
2019 Standout
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
2014 Nature
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials
2013 Standout
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
2016
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
2013
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
2014
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
2017
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Prostate cancer
2015
Hepatocellular carcinoma
2021 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Immunogenic cell death in cancer and infectious disease
2016 Standout
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
2012
Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis
2015
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
2015
Delivery technologies for cancer immunotherapy
2019 Standout
Androgen receptor: structure, role in prostate cancer and drug discovery
2014
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
2016
RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
2016
New Therapeutics to Treat Castrate‐Resistant Prostate Cancer
2013
Measuring the multifaceted roles of mucin-domain glycoproteins in cancer
2022 StandoutNobel
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Dormant tumour cells, their niches and the influence of immunity
2018
Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer
2013
Implementing Genome-Driven Oncology
2017
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 Standout
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
Common pitfalls in preclinical cancer target validation
2017 StandoutNobel
Trial watch: Dendritic cell-based anticancer therapy
2014
Emerging Biological Principles of Metastasis
2017 Standout
Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
2014
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
2015 Nature
Cancer treatment and survivorship statistics, 2012
2012 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Targeting metastasis
2016
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
2018
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Prostate cancer in the elderly
2011
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable
2019 Standout
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
2018
AKT/PKB Signaling: Navigating the Network
2017 Standout
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
2018
Efficient generation of mouse models of human diseases via ABE- and BE-mediated base editing
2018 Standout
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
2017
Eating Patterns and Risk of Colon Cancer
1998 Standout
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
2017
Induced protein degradation: an emerging drug discovery paradigm
2016
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase
2017 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
A study of the reliability and comparative validity of the cardia dietary history.
1994
Long Noncoding RNA and Cancer: A New Paradigm
2017 Standout
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
2014
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
2017
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial
2014
Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
2013
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
2013
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
2013
Amplification of MUC1 in prostate cancer metastasis and CRPC development
2016
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
Overcoming mutation-based resistance to antiandrogens with rational drug design
2013
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials
2017
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
2014
Colorectal cancer statistics, 2017
2017 Standout
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio
2014
Combination therapy in combating cancer
2017 Standout
KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment
2014
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
2014 StandoutNobel
Cancer treatment and survivorship statistics, 2016
2016 Standout
No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year period
2013
NCCN Task Force Report: Bone Health in Cancer Care
2013
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Metastatic Prostate Cancer
2018
Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics
2017 StandoutNobel
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Industry sponsorship and research outcome
2017 Standout
Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer
2013
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Bryan Selby being referenced
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.
2012